Raymond James analyst Jayson Bedford reiterated a Buy rating on Boston Scientific Corp (BSX) on December 28 and set a price target of $42. The company’s shares closed yesterday at $35.34.
According to TipRanks.com, Bedford is a top 100 analyst with an average return of 18.0% and a 67.5% success rate. Bedford covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Johnson & Johnson, and BioTelemetry.
Currently, the analyst consensus on Boston Scientific Corp is a Strong Buy with an average price target of $42.88, implying a 21.3% upside from current levels. In a report issued on December 17, Credit Suisse also initiated coverage with a Buy rating on the stock with a $42 price target.
.
See today’s analyst top recommended stocks >>
Based on Boston Scientific Corp’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.39 billion and net profit of $432 million. In comparison, last year the company earned revenue of $2.22 billion and had a net profit of $283 million.
Based on the recent corporate insider activity of 140 insiders, corporate insider sentiment is negative on the stock. Most recently, in November 2018, Thepaut Eric Francis Yves, the SVP & Pres, Eur, Mid-East, Afr of BSX sold 23,458 shares for a total of $879,675.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Cardiovascular, Rhythm Management, and MedSurg.
